Daiwa Capital Markets Downgrades Takeda Pharmaceutical (NYSE:TAK) to Neutral

Daiwa Capital Markets lowered shares of Takeda Pharmaceutical (NYSE:TAK) from an outperform rating to a neutral rating in a research report released on Thursday morning, Briefing.com Automated Import reports.

A number of other research firms have also recently weighed in on TAK. Zacks Investment Research cut shares of Takeda Pharmaceutical from a buy rating to a hold rating in a report on Wednesday, August 7th. ValuEngine cut shares of Takeda Pharmaceutical from a hold rating to a sell rating in a report on Wednesday, May 15th.

TAK stock opened at $16.72 on Thursday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.01 and a current ratio of 1.46. Takeda Pharmaceutical has a fifty-two week low of $15.50 and a fifty-two week high of $21.95. The business has a 50-day moving average price of $17.52. The firm has a market cap of $26.34 billion, a PE ratio of 32.78 and a beta of 0.69.

Several hedge funds have recently added to or reduced their stakes in the stock. HM Payson & Co. acquired a new position in shares of Takeda Pharmaceutical in the second quarter worth about $80,000. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Takeda Pharmaceutical by 6.6% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 40,712 shares of the company’s stock worth $716,000 after buying an additional 2,509 shares during the period. Prestige Wealth Management Group LLC acquired a new position in shares of Takeda Pharmaceutical in the second quarter worth about $25,000. Voloridge Investment Management LLC acquired a new position in shares of Takeda Pharmaceutical in the second quarter worth about $385,000. Finally, Covenant Partners LLC boosted its holdings in shares of Takeda Pharmaceutical by 7.6% in the second quarter. Covenant Partners LLC now owns 63,483 shares of the company’s stock worth $1,124,000 after buying an additional 4,480 shares during the period. 11.31% of the stock is currently owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Article: How does the Beige Book influence monetary policy?

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.